As Sol, I'm willing to bet money on this. The cash burn rate is just too hight. To many overpaid ppl on the payroll and a lot of cash out of the window for various conferences.
LymPro is not going to get any significant revenue in 2014 (if at all) and we dont know if a partner is going to give AMBS any upfront money for LymPro data based on a study with 10 (TEN) AD patients. AMBS might have to pay them first, until the test proves to be good selling product.
Market Data 
Markets 
AI
